Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Exon-Skipping Franchise Buys Sarepta A Second Chance
06:19am, Wednesday, 17'th Mar 2021
SRPT's lucrative Exon-Skipping franchise allows the company to buy a second chance, even if its SRP 9001 project fails.
Rocket Pharmaceuticals Primed for Takeoff
06:19pm, Monday, 15'th Mar 2021
With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.
-- Ten abstracts, including four podium presentations, reflect Sarepta's ongoing commitment to advancing genetic medicine for rare neuromuscular disease and facilitating greater understanding of these
Despite A Q4 Miss Sarepta Therapeutics Stock Could See Higher Levels
02:00pm, Tuesday, 02'nd Mar 2021
Despite A Q4 Miss Sarepta Therapeutics Stock Could See Higher Levels[Updated 3/2/2021] Sarepta Update Last month we talked about how Sarepta Therapeutics stock (NASDAQ: SRPT) seems to be a good buying
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates
10:36am, Tuesday, 02'nd Mar 2021
Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.
Sarepta Therapeutics Drops on Earnings. Why Analysts Remain Hopeful.
08:57am, Tuesday, 02'nd Mar 2021
Sarepta Therapeutics stock fell as markets digested its bigger-than-expected quarterly loss. But analysts say the setup for the stock remains positive.
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2020 Results - Earnings Call Transcript
01:07am, Tuesday, 02'nd Mar 2021
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2020 Results - Earnings Call Transcript
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
06:57pm, Monday, 01'st Mar 2021
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -20.00% and 1.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock
Recap: Sarepta Therapeutics Q4 Earnings
04:28pm, Monday, 01'st Mar 2021
Shares of Sarepta Therapeutics (NASDAQ:SRPT) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 17.20% over the past year to ($1.84
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
04:05pm, Monday, 01'st Mar 2021
– Net product sales for the fourth quarter and full-year 2020 of $122.6 million and $455.9 million, respectively, were pre-announced in January 2021 at the J.P. Morgan Healthcare Conference –
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:12pm, Friday, 26'th Feb 2021
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 26, 2021 that we
Earnings Preview: Sarepta Therapeutics
10:16am, Friday, 26'th Feb 2021
Sarepta Therapeutics (NASDAQ:SRPT) announces its next round of earnings this Monday, March 01. Here is Benzinga's everything-that-matters guide for this Monday's Q4 earnings announcement.
Sarepta stock rises after FDA approves biotech's Duchenne MD treatment
03:48pm, Thursday, 25'th Feb 2021
Shares of Sarepta Therapeutics Inc. rose nearly 1% in late trading Thursday after the biotech company said the U.S. Food and Drug Administration has approved one of its treatments for Duchenne muscula
-- AMONDYS 45 is Sarepta's third RNA exon-skipping treatment for DMD approved in the U.S. ---- Commercial distribution of AMONDYS 45 in the U.S. will commence immediately ---- Information for patients
Sarepta Therapeutics to Present at Upcoming Investor Conferences
04:30pm, Wednesday, 24'th Feb 2021
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pa
